Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin
Authors:
- M.J. KovacsMKM.J. Kovacs
- C. KearonCKC. Kearon
- M. RodgerMRM. Rodger
- D.R. AndersonDAD.R. Anderson
- A.G.G. TurpieATA.G.G. Turpie
- S.M. BatesSBS.M. Bates
- L. DesjardinsLDL. Desjardins
- J. DouketisJDJ. Douketis
- S.R. KahnSKS.R. Kahn
- S. SolymossSSS. Solymoss
- P.S. WellsPWP.S. Wells
- 21 September 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (12) , 1658-1663
Abstract
Background— When warfarin is interrupted for surgery, low-molecular-weight heparin is often used as bridging therapy. However, this practice has never been evaluated in a large prospective study. This study was designed to assess the efficacy and safety of bridging therapy with low-molecular-weight heparin initiated out of hospital. Methods and Results— This was a prospective, multicenter, single-arm cohort study of patients at high risk of arterial embolism (prosthetic valves and atrial fibrillation with a major risk factor). Warfarin was held for 5 days preoperatively. Low-molecular-weight heparin was given 3 days preoperatively and at least 4 days postoperatively. Patients were followed up for 3 months for thromboembolism and bleeding. Eleven Canadian tertiary care academic centers participated; 224 patients were enrolled. Eight patients (3.6%; 95% CI, 1.8 to 6.9) had an episode of thromboembolism, of which 2 (0.9%; 95% CI, 0.2 to 3.2) were judged to be due to cardioembolism. Of these 8 episodes of thromboembolism, 6 occurred in patients who had warfarin deferred or withdrawn because of bleeding. There were 15 episodes of major bleeding (6.7%; 95% CI, 4.1 to 10.8): 8 occurred intraoperatively or early postoperatively before low-molecular-weight heparin was restarted, 5 occurred in the first postoperative week after low-molecular-weight heparin was restarted, and 2 occurred well after low-molecular-weight heparin was stopped. There were no deaths. Conclusions— Bridging therapy with subcutaneous low-molecular-weight heparin is feasible; however, the optimal approach for the management of patients who require temporary interruption of warfarin to have invasive procedures is uncertain.Keywords
This publication has 23 references indexed in Scilit:
- Indications, methodology, and classification of results of tilt-table testing11This article may contain discussion of off-label or investigational uses (not yet approved by the FDA) of various therapeutic agents. Please refer to the box provided on page 2Q of this supplement for a disclosure of such agents.The American Journal of Cardiology, 1999
- Expanding Eligibility for Outpatient Treatment of Deep Venous Thrombosis and Pulmonary Embolism With Low-Molecular-Weight HeparinArchives of internal medicine (1960), 1998
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous ThromboembolismNew England Journal of Medicine, 1997
- Management of Anticoagulation before and after Elective SurgeryNew England Journal of Medicine, 1997
- Prosthetic Heart ValvesNew England Journal of Medicine, 1996
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart ValvesChest, 1995
- Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.Circulation, 1994
- Anticoagulation for Noncardiac Procedures in Patients With Prosthetic Heart ValvesJAMA, 1990
- The management of anticoagulation during noncardiac operations in patients with prosthetic heart valvesAmerican Heart Journal, 1978